FLAGSHIP IS PRESENTING A POSTER AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 34TH ANNUAL MEETINGNovember 6-10, 2019 Gaylord National Hotel and Convention Center, National Harbor, MD Flagship is presenting a scientific poster on November 8th at the meeting in...
WEBINAR – IMPROVING PD-L1 SCORING WITH IMAGE ANALYSISOctober 9, 2019 1 PM EDT/10 AM PDT on “Improving PD-L1 Scoring with Image Analysis”.
ANALYTICAL ADVANCEMENTS TO POWER BIOMARKER DEVELOPMENT TRACK PRESENTATION: ADDING VALUE TO TRADITIONAL IN VITRO DIAGNOSTICS (IVDS) AT WORLD CB&CDXSeptember 12, 2019 at 2:50pm The Renaissance Boston Waterfront, Boston, MA Speaker: Kelsey Weigel, PhD, Scientist II,...
WORLD CB AND CDX BOSTON 2019 (CLINICAL BIOMARKER AND COMPANION DIAGNOSTICS)September 9-12, 2019 The Renaissance Boston Waterfront, Boston, MA Flagship Biosciences is a proud Spotlight Partner of World CB and CDx Boston 2019. Flagship’s leaders will be speaking and...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Cambridge, MA and Westminster, CO — May 12, 2021 — Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today...
Laboratory Developed Test for Manual and Image Analysis-assisted Pathologist InterpretationCambridge, MA and Westminster, CO – April 12, 2021 — Flagship Biosciences, the leader in data-centric pathology and tissue analysis, and Leap Therapeutics (Nasdaq: LPTX), a...
Dr. Roberto Gianani and Michael Koratich Named to Key Medical and Pharma RolesWestminster, CO – March 10, 2021 – Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced strategic additions to its executive team. Dr. Roberto...
PUBLICATIONS/POSTERS
Artificial intelligence (AI) systems for pathology may appear to compete with manual pathology, as they enable the assessment of thousands of cells and application of complex scoring schemes beyond the capacity of a human pathologist. However, this technology...
CIOReview named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review. “The ease of leveraging Flagship’s powerful solution is yet another massive...
Key Concepts: Pathological interpretations applied to PD-L1 IHC as a response biomarker are becoming more complex, going beyond simple tumor proportion score (TPS) and requiring more complex diagnostic algorithms that evaluate the role of PDL1 expression in tumor...